Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors - Waibel, M; Solomon, V S; Knight, D A (Cell Rep, 2013)